Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
- Royalty Pharma: welcome clarity mixed with unwelcome ambiguity 15-05-2020
- Will Big Pharma get the bug for microbiome therapies? 06-05-2020
- Why things could get ugly over COVID-19 patents 30-04-2020
- COVID-19: governments look to shield companies from IP enforcement 23-04-2020
- Patent pools: should rights owners give up their IP? 21-04-2020
Latest news
FDA warns of ‘grave’ knock-on effects from Eagle decision
29-05-2020
The US Food and Drug Administration has warned a US Court of Appeals for the DC Circuit decision awarding market exclusivity to Eagle Pharmaceuticals for a cancer drug will have “grave” consequences for patient access.
